TCI Wealth Advisors’s Elicio Therapeutics ELTX Stock Holding History

TCI Wealth Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4	Closed	–	–	2427
2021 Q2	$0	Buy	+4	New	+$577	﹤0.01%	2352

Other funds holding ELTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TCI Wealth Advisors's ELTX Position: Q3 2021 in Review

TCI Wealth Advisors sold out of Elicio Therapeutics (ELTX) in Q3 2021, closing a stake of 4 shares.

TCI Wealth Advisors first reported a position in ELTX in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q3 2021.

TCI Wealth Advisors reported no remaining Elicio Therapeutics position as of Q3 2021 after selling out during the quarter.
TCI Wealth Advisors sold 4 Elicio Therapeutics shares in Q3 2021.
TCI Wealth Advisors first reported a position in Elicio Therapeutics in Q2 2021 and held it in 1 quarter.
TCI Wealth Advisors's Elicio Therapeutics position peaked at $0 in Q2 2021.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2021.

Based on TCI Wealth Advisors's 13F filing for Q3 2021, filed 29 Oct 2021.